SG11201900895QA - Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy - Google Patents

Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy

Info

Publication number
SG11201900895QA
SG11201900895QA SG11201900895QA SG11201900895QA SG11201900895QA SG 11201900895Q A SG11201900895Q A SG 11201900895QA SG 11201900895Q A SG11201900895Q A SG 11201900895QA SG 11201900895Q A SG11201900895Q A SG 11201900895QA SG 11201900895Q A SG11201900895Q A SG 11201900895QA
Authority
SG
Singapore
Prior art keywords
self
international
protein
assay
michael
Prior art date
Application number
SG11201900895QA
Other languages
English (en)
Inventor
Michael Marlow
Michael Sennett
Michael Schneider
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201900895QA publication Critical patent/SG11201900895QA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587Nanoparticles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N2021/258Surface plasmon spectroscopy, e.g. micro- or nanoparticles in suspension

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
SG11201900895QA 2016-08-18 2017-08-18 Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy SG11201900895QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662376788P 2016-08-18 2016-08-18
PCT/US2017/047630 WO2018035470A1 (fr) 2016-08-18 2017-08-18 Test de détermination du potentiel d'auto-association d'une protéine utilisant la spectroscopie de nanoparticules à auto-interaction dépendante de la concentration

Publications (1)

Publication Number Publication Date
SG11201900895QA true SG11201900895QA (en) 2019-02-27

Family

ID=59746357

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900895QA SG11201900895QA (en) 2016-08-18 2017-08-18 Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy

Country Status (18)

Country Link
US (2) US11428695B2 (fr)
EP (2) EP3500856B1 (fr)
JP (3) JP6959327B2 (fr)
KR (3) KR102441221B1 (fr)
CN (2) CN109661577B (fr)
AU (2) AU2017313150B2 (fr)
BR (1) BR112019003175A2 (fr)
CA (1) CA3032361A1 (fr)
DK (2) DK3761035T3 (fr)
EA (1) EA201990316A1 (fr)
ES (1) ES2837093T3 (fr)
FI (1) FI3761035T3 (fr)
HU (1) HUE052805T2 (fr)
IL (2) IL264640B2 (fr)
MX (1) MX2019001930A (fr)
PL (1) PL3500856T3 (fr)
SG (1) SG11201900895QA (fr)
WO (1) WO2018035470A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3500856B1 (fr) 2016-08-18 2020-10-07 Regeneron Pharmaceuticals, Inc. Méthode pour determiner le potentiel à l'autoassociation d'une proteine à l'aide de la spectroscopie de l'autoassociation des nanoparticules dépendante de la concentration
WO2019217927A1 (fr) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. Formulations contenant des protéines de fusion du récepteur vegf à haute concentration
CN113588582B (zh) * 2020-04-30 2024-05-14 上海药明生物技术有限公司 蛋白质样品浓度测定方式选择法及测定方法
WO2023095154A1 (fr) * 2021-11-24 2023-06-01 Sensoville Biotech Pvt Ltd Procédé de détermination de changements de structure de protéine
WO2023141319A1 (fr) * 2022-01-24 2023-07-27 Amgen Inc. Méthodes de détection d'autoassociation d'anticorps

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US771997A (en) 1903-11-21 1904-10-11 Alfred Palm Lathe attachment.
US4254102A (en) * 1975-09-08 1981-03-03 Plough, Inc. Substantive PABA compositions
US4080264A (en) 1976-03-01 1978-03-21 Massachusetts Institute Of Technology Immunoassay by light scattering spectroscopy
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7514938B2 (en) 2004-05-11 2009-04-07 Board Of Regents Of The University And College System Of Nevada, On Behalf Of The University Of Nevada, Reno Dielectric relaxation spectroscopy apparatus and methods of use
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
WO2007121363A2 (fr) 2006-04-13 2007-10-25 Mississippi State University Appareil optique permettant de mesurer simultanément les signaux de diffusion et de concentration de macromolécules dans une cuve à circulation
RU2009111138A (ru) * 2006-10-12 2010-11-20 Вайет (Us) Способы и композиции с уменьшенной опалесценцией
EP2150617B1 (fr) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Régions d'expression et de stabilité amplifiées
US20090104114A1 (en) * 2007-09-21 2009-04-23 Cytimmune Sciences, Inc. Nanotherapeutic Colloidal Metal Compositions and Methods
WO2010059963A2 (fr) * 2008-11-21 2010-05-27 The Board Of Regents Of The University Of Texas System Préparation et méthodologie de nanoparticules de fibroïne de soie
EP2993460B1 (fr) * 2013-05-30 2019-07-03 Osaka Prefecture University Public Corporation Appareil et procédé de détection de substance cible
KR20240042200A (ko) * 2013-09-11 2024-04-01 이글 바이오로직스 인코퍼레이티드 점도저하제를 함유하는 액체 단백질 제형
US20160074515A1 (en) * 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
CN104062287B (zh) * 2014-07-01 2017-08-08 福建工程学院 一种基于纳米金催化的化学发光分析检测铁蛋白的方法
MA40861A (fr) * 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
US20180264112A1 (en) * 2015-01-18 2018-09-20 Biogen Ma Inc. Anti-CD40 Antibody Formulations
EP3500856B1 (fr) 2016-08-18 2020-10-07 Regeneron Pharmaceuticals, Inc. Méthode pour determiner le potentiel à l'autoassociation d'une proteine à l'aide de la spectroscopie de l'autoassociation des nanoparticules dépendante de la concentration

Also Published As

Publication number Publication date
JP7321227B2 (ja) 2023-08-04
WO2018035470A9 (fr) 2018-07-05
US11988668B2 (en) 2024-05-21
US20220357335A1 (en) 2022-11-10
FI3761035T3 (fi) 2024-03-18
ES2837093T3 (es) 2021-06-29
WO2018035470A1 (fr) 2018-02-22
BR112019003175A2 (pt) 2019-06-18
JP6959327B2 (ja) 2021-11-02
DK3761035T3 (da) 2024-03-11
JP2019532267A (ja) 2019-11-07
IL264640B1 (en) 2023-11-01
KR102441221B1 (ko) 2022-09-07
IL307435A (en) 2023-12-01
KR20220126801A (ko) 2022-09-16
AU2017313150B2 (en) 2023-09-14
EP3761035A1 (fr) 2021-01-06
KR20190039185A (ko) 2019-04-10
IL264640B2 (en) 2024-03-01
CN109661577B (zh) 2022-09-27
KR20230074614A (ko) 2023-05-30
CN115468919A (zh) 2022-12-13
JP2022008959A (ja) 2022-01-14
KR102534506B1 (ko) 2023-05-30
HUE052805T2 (hu) 2021-05-28
CA3032361A1 (fr) 2018-02-22
PL3500856T3 (pl) 2021-04-19
AU2017313150A1 (en) 2019-02-21
US11428695B2 (en) 2022-08-30
EP3500856A1 (fr) 2019-06-26
EP3500856B1 (fr) 2020-10-07
MX2019001930A (es) 2019-07-04
DK3500856T3 (da) 2020-12-14
JP2023139189A (ja) 2023-10-03
IL264640A (fr) 2019-04-30
EA201990316A1 (ru) 2019-07-31
CN109661577A (zh) 2019-04-19
US20190187149A1 (en) 2019-06-20
AU2023274236A1 (en) 2023-12-21
EP3761035B1 (fr) 2024-02-14

Similar Documents

Publication Publication Date Title
SG11201900895QA (en) Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201903674YA (en) Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201903889TA (en) Crenolanib for treating flt3 mutated proliferative disorders associated mutations
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201908650PA (en) Optimized antibody compositions for treatment of ocular disorders
SG11201906301UA (en) Methods of manufacture of nut flours and formulations for oral immunotherapy
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201908092RA (en) Anti-tigit antigen-binding proteins and methods of use thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201901228QA (en) Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
SG11201808592PA (en) Method for selection of high m6p recombinant proteins